EP1521580A1 - Nouvelles compositions medicamenteuses a base de nouveaux anticholinergiques et antagonistes du recepteur nk1 - Google Patents

Nouvelles compositions medicamenteuses a base de nouveaux anticholinergiques et antagonistes du recepteur nk1

Info

Publication number
EP1521580A1
EP1521580A1 EP03762508A EP03762508A EP1521580A1 EP 1521580 A1 EP1521580 A1 EP 1521580A1 EP 03762508 A EP03762508 A EP 03762508A EP 03762508 A EP03762508 A EP 03762508A EP 1521580 A1 EP1521580 A1 EP 1521580A1
Authority
EP
European Patent Office
Prior art keywords
acid
phenyl
alkyl
inhalation
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03762508A
Other languages
German (de)
English (en)
Inventor
Michel Pairet
Christopher John Montague Meade
Michael P. Pieper
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1521580A1 publication Critical patent/EP1521580A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel pharmaceutical compositions based on new anticholinergics and NK-i receptor antagonists, methods for their
  • the present invention relates to novel pharmaceutical compositions based on new anticholinergics and NK-j receptor antagonists, and processes for their use
  • an unexpectedly advantageous therapeutic effect in particular a synergistic effect in the treatment of inflammatory and / or obstructive respiratory diseases, can be observed if one or more, preferably a new anticholinergic of formula 1 together with one or more, preferably an NK-j receptor Antagonists 2 are used. Because of this synergistic effect, the pharmaceutical combinations according to the invention can be used in lower doses than is the case with the otherwise customary monotherapy of the individual compounds. is.
  • the active compound combinations according to the invention are surprisingly characterized both by a rapid onset of action and by a long duration of action. This is of great importance for the well-being of the patient, since on the one hand he quickly after application of the combination
  • salts of formula 1 are used as anticholinergic wherein
  • X ' is a single negatively charged anion, preferably an anion selected from the group consisting of chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate,
  • Fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulfonate means use.
  • X _ is a simply negatively charged anion selected from the group
  • Chloride bromide, 4-toluenesulfonate and methanesulfonate, preferably bromide.
  • the salts of the formula I are particularly preferably used in which X "is a simply negatively charged anion selected from the group
  • the salt of formula 1 in which X "represents bromide is particularly preferred.
  • a reference in the context of the present invention to the salts which can be used according to the invention includes optionally available hydrates and solvates of these compounds.
  • receptor antagonists are understood to mean compounds which are selected from the group consisting of N- [2- (3,5-bis-trifluoromethylphenyl) ethyl] - 2- ⁇ 4-cyclopropylmethyl-piperazin-1-yl ⁇ -N-methyl-2-phenyl-acetamide (BIIF 1149), CP-122721, FK-888, NKP 608C, NKP 608A, CGP 60829, SR 48968 (Saredutant) , SR 140333 (Nolpitantium besilate / chloride), LY 303 870 (Lanepitant), MEN-11420 (Nepadutant), SB 223412, MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, SR-144190, YM-49244, YM-44778, ZM-274773, MEN-10930
  • R 6 H -C ⁇ -Cs-alkyl, C3-C5-alkenyl, propynyl, hydroxy (C2-C4) alkyl, methoxy (C2-C-4) alkyl, di (C ⁇ -C3) alkylamino (C2-C4) alkyl , Amino (C2-C4) alkyl, amino, di (C-
  • R 7 has one of the meanings (a) to (d),
  • R ⁇ 6 and R 17 independently of one another are H, (-C-C4) alkyl, (C3-C6) cycloalkyl, hydroxy (C2-C4) alkyl, dihydroxy (C2-C4) alkyl, (C ⁇ -C3) alkoxy (C2- C4) alkyl, phenyl (C- ⁇ - C4) alkyl or di (C-
  • R 8 denotes H, optionally in the form of their enantiomers and mixtures of
  • Compound 2 is preferably selected from the group consisting of BIIF 1149, CP-122721, CGP 60829, MK-869, CJ-11974, GR 205171 and the arylglycinamide derivatives of the general formula 3, in which R1 and R 2 together with the N they are bound, a ring of the formula
  • R 16 and R ⁇ 7 independently of one another are H, (C- ⁇ -C4) alkyl, (C3-C6) cycloalkyl, hydroxy (C2-C4) alkyl, dihydroxy (C2-C4) alkyl, (C ⁇ -C3) alkoxy ( C2-C4) alkyl, phenyl (Cj-C4) alkyl or di (C-
  • R 8 denotes H, optionally in the form of their enantiomers and mixtures of the enantiomers, and optionally in the form of their racemates.
  • the compound 2 is particularly preferably selected from BIIF1149 and the arylglycinamide derivatives of the general formula 3, in which R 1 and R 2 together with the N to which they are attached form a ring of the formula
  • R 17 stands,
  • R 16 and R 17 are independent of one another
  • R 8 denotes H, optionally in the form of their enantiomers and mixtures of the enantiomers, and optionally in the form of their
  • N- [2- (3,5-bis-trifluoromethylphenyl) ethyl] -2- ⁇ 4 - [(3-hydroxypropyl) methylamino] piperidine-1- are very particularly preferred as compounds.
  • alkyl groups with ibis 5 carbon atoms are considered as alkyl groups (also insofar as they are part of other radicals). Examples include: methyl, ethyl, propyl, 1-methylethyl (isopropyl), n-butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl (tert-butyl), etc.
  • propyl, Butyl and pentyl die respective isomeric residues always included.
  • Hydroxy or dihydroxyalkyl groups are alkyl groups which are substituted by one or two hydroxy groups.
  • Alkenyl groups are branched and unbranched alkenyl groups with 3 to 5 carbon atoms, provided that they have at least one double bond, such as propenyl, isopropenyl, butenyl etc.
  • Cycloalkyl generally represents a saturated cyclic hydrocarbon radical having 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopropylethyl, cyclobutylethyl etc.
  • Alkyloxy which may also be referred to as alkoxy, stands for a straight-chain or branched alkyl group bonded via an oxygen atom.
  • the methoxy group is particularly preferred.
  • a reference to the aforementioned NK-j receptor antagonists 2 includes a reference to their pharmacologically acceptable acid addition salts which may exist.
  • the physiologically compatible acid addition salts which can be formed by 2 are understood to be pharmaceutically compatible salts which are selected from the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid ,
  • the pharmaceutical combinations according to the invention from 1 and 2 are preferably administered by inhalation.
  • Suitable inhalable powders which are filled into suitable capsules (inhalettes) and applied by means of appropriate powder inhalers, can be used.
  • inhalative use can also be carried out by applying more suitable ones
  • Inhalation aerosols take place.
  • This also includes powdered inhalation aerosols, which contain, for example, HFA134a, HFA227 or their mixture as propellant.
  • Inhalation can also be carried out using suitable solutions of the drug combination consisting of 1 and 2.
  • One aspect of the present invention accordingly relates to a medicament which contains a combination of 1 and 2.
  • Another aspect of the present invention relates to a medicament which contains one or more salts i and one or more compounds 2, optionally in the form of their solvates or hydrates.
  • the active substances can either be contained together in a single dosage form or in two separate dosage forms.
  • the present invention further relates to the use of 1 and 2 for the production of a therapeutically effective amount of medicament containing 1 and 2 for the treatment of inflammatory or obstructive respiratory diseases, in particular asthma or chronic obstructive pulmonary diseases (COPD), and their complications such as, for example, pulmonary hypertension , also allergic and non-allergic rhinitis, provided treatment with NK ⁇ ⁇ receptor antagonists is not contraindicated from a therapeutic point of view, by simultaneous or successive application.
  • inflammatory or obstructive respiratory diseases in particular asthma or chronic obstructive pulmonary diseases (COPD)
  • COPD chronic obstructive pulmonary diseases
  • the present invention further aims at the simultaneous or successive use of therapeutically effective doses of the combination of the above medicinal products 1 and 2 for the treatment of inflammatory and / or obstructive respiratory diseases, in particular asthma or chronic obstructive pulmonary disease (COPD), and their complications such as, for example, pulmonary hypertension, in addition, allergic and non-allergic rhinitis, provided treatment with NK -] receptor antagonists is not contraindicated from a therapeutic point of view, by simultaneous or successive application.
  • inflammatory and / or obstructive respiratory diseases in particular asthma or chronic obstructive pulmonary disease (COPD)
  • COPD chronic obstructive pulmonary disease
  • constituents 1 and 2 can be present in the form of their enantiomers, mixtures of the enantiomers or in the form of the racemates.
  • the ratios in which the two active ingredients 1 and 2 can be used in the active ingredient combinations according to the invention are variable.
  • the active ingredients 1 and 2 can optionally be in the form of their solvates or hydrates.
  • the weight ratios which can be used in the context of the present invention vary on account of the different molecular weight of the different compounds and on the basis of their different potency.
  • the pharmaceutical combinations according to the invention can contain the compounds 1 and 2 in weight ratios which are in a range from 1: 100 to 100: 1, preferably from 1:80 to 80: 1.
  • preferred combinations according to the invention of 1 and 2 can contain the cation V and NK-j receptor antagonist 2 in the following weight ratios: 1:50; 1:49; 1:48; 1:47; 1:46; 1:45; 1:44; 1:43; 1:42; 1:41; 1:40; 1:39; 1:38; 1:37; 1:36; 1:35; 1:34; 1:33; 1:32; 1:31; 1:30; 1:29; 1:28; 1:27; 1:26; 1:25; 1:24; 1:23; 1:22; 1:21; 1:20; 1:19; 1:18; 1:17; 1:16; 1:15; 1:14; 1:13; 1:12; 1:11; 1:10; 1: 9; 1: 8; 1: 7; 1: 6; 1: 5; 1: 4; 1: 3; 1: 2; 1: 1; 2: 1; 3: 1; 4: 1; 5: 1; 6: 1; 7: 1; 7: 1; 7: 1; 7: 1; 7
  • compositions according to the invention containing the combinations of 1 and 2 are normally administered so that 1 and 2 g together in dosages of 0.01 to 10000, preferably from 0.1 to 2000 g, more preferably from 1 to 1500 ⁇ g, further preferably from 50 to 1200 / g per single dose are included.
  • combinations of ⁇ and 2 according to the invention contain such a combination Amount of V and NKi receptor antagonist 2 that the total dose per single dose is 100 / yg, 105 / yg, 110 / yg, 115 / yg, 120 / yg, 125 / yg, 130 / yg, 135 / g, 140 / yg, 145 / yg, 150 / yg, 155 / yg, 160 / tg, 165 / yg, 170 / y g, 175 / y g, 180 / y g, 185 // g, 190 / yg, 195 / yg, 200 / yg, 205 / yg, 210 / yg, 215 / yg, 220 / yg, 225 / y g, 230 / y g, 235 // g, 240 /
  • the combinations according to the invention from 1 and 2 may contain such an amount of V and NKi receptor antagonist 2 that 16.5 / yg V and 25 / yg 2, 16, 5 / y g V and 50yg 2, 16.5 / yg V and 100yg 2, 16.5yg V and 200yg 2, 16.5 / g V and 300 y g 2, 16.5yg V and 400 / yg 2, 16 , 5 y g V and 500 / yg 2, 16.5 / y g V and 600 / yg 2, 16.5 / y g V and 700 / yg 2, 16.5yg and 800 / yg 2, 16.5 / yg JT and 900yg 2, 16.5 / yg V and 1000 / yg 2, 33, 1 g and 25 / y g 2, 33, 1 / yg and 50yg 2, 33, 1 gr and 100 / yg 2, 33, 1
  • the active ingredient amounts of r and 2 given above by way of example correspond to the subsequent amounts of 1 and 2: 20 / yg 1 and applied per single administration 25 // g 2, 20 / yg 1 and 50 / yg 2, 20 / yg 1 and 100 / yg 2, 20 / yg 1 and 200 / yg 2, 20 / yg 1 and 300 // g 2, 20 / yg 1 and 400 / yg 2, 20 / g 1 and 500 / yg 2, 20 yg 1 and 600 / yg 2, 20 / yg 1 and 700 / yg 2, 20 / yg 1 and 800 / yg 2, 20 / yg 1 and 900 / yg 2, 20 / yg 1 and
  • the active ingredient combinations according to the invention from 1 and 2 are preferably administered by inhalation.
  • components 1 and 2 must be provided in inhalable dosage forms.
  • Inhalable dosage forms are inhalable powders, metered-dose aerosols containing propellant gas, or propellant-free inhalation solutions.
  • Inhalable powders according to the invention containing the combination of active substances 1 and 2 can consist solely of the active substances mentioned or of a mixture of the active substances mentioned with physiologically compatible auxiliaries.
  • propellant-free inhalation solutions also includes concentrates or sterile, ready-to-use inhalation solutions.
  • the dosage forms according to the invention can contain the active ingredient combination from 1 and 2 either together in one or in two separate dosage forms.
  • the inhalable powders according to the invention can contain ⁇ and 2 either alone or in a mixture with suitable physiologically acceptable excipients.
  • the active ingredients 1 and 2 are contained in a mixture with physiologically acceptable auxiliaries
  • the following physiologically acceptable auxiliaries can be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, sucrose, maltose, trehalose), oligo and polysaccharides (for example dextrans), polyalcohols (for example sorbitol, mannitol, xylitol), salts (for example sodium chloride, calcium carbonate) or mixtures of these auxiliaries with one another.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, sucrose, maltose, trehalose
  • oligo and polysaccharides for example dextrans
  • polyalcohols for example sorbitol, mannitol, xylitol
  • salts for example sodium chloride,
  • Mono- or disaccharides are preferably used, the use of lactose or glucose being preferred, in particular, but not exclusively, in the form of their hydrates.
  • Lactose most preferably lactose monohydrate, is used as an auxiliary as particularly preferred in the sense of the invention.
  • the auxiliaries have a maximum average particle size of up to 250 / ym, preferably between 10 and 150 / ym, particularly preferably between 15 and 80 / ym. If necessary, it may seem sensible to finer the above-mentioned auxiliary substances
  • micronized active ingredients 1 and 2 preferably with an average particle size of 0.5 to 10 / ym, particularly preferably 1 to 6 / ym, are admixed with the excipient mixture.
  • Processes for producing the inhalable powders according to the invention by grinding and micronizing and by finally mixing the constituents are known from the prior art.
  • the inhalable powders according to the invention can be provided and applied either in the form of a single powder mixture which contains both 1 and 2 or in the form of separate inhalable powders which contain only 1 and 2.
  • the inhalable powders according to the invention can be applied using inhalers known from the prior art.
  • Inhalation powders according to the invention which in addition to ⁇ and 2 also contain a physiologically acceptable auxiliary, can be applied, for example, by means of inhalers, which take a single dose from a supply by means of a measuring chamber, as described in US Pat. No. 4,570,630A, or via other apparatus, such as the one described are described in DE 3625 685 A, meter.
  • the inhalable powders according to the invention, which in addition to 1 and 2 contain physiologically acceptable excipients, are preferably filled into capsules (for so-called inhalers), which are used in inhalers as described, for example, in WO 94/28958.
  • FIG. 1 An inhaler which is particularly preferred for use of the pharmaceutical combination according to the invention in inhalettes can be seen in FIG. 1.
  • This inhaler for inhaling powdered pharmaceuticals from capsules is characterized by a housing 1, containing two windows 2, a deck 3, in which there are air inlet openings and which is provided with a sieve 5 fastened via a sieve housing 4, one with a deck 3 connected inhalation chamber 6, on which a pusher 9 provided with two ground needles 7 and movable against a spring 8 is provided, and a pusher connected to the housing 1, the deck 3 and a cap 11 via an axis 10 Mouthpiece 12, and Lut mallklalöcher 13 for adjusting the flow resistance.
  • inhalable powders according to the invention are to be filled into capsules (inhalettes) in the sense of the preferred use mentioned above, fill quantities of 1 to 30 mg, preferably 3 to 20 mg, preferably 5 to 10 mg inhalable powder per capsule are appropriate. According to the invention, these contain either together or in each case the doses per single dose already mentioned above for V and 2.
  • Inhalation aerosols containing propellant gas according to the invention can contain ⁇ and 2 dissolved in the propellant gas or in dispersed form.
  • 1 and 2 can be contained in separate dosage forms or in a common dosage form, where 1 and 2 can either be both dissolved, both dispersed or in each case only one component dissolved and the other dispersed.
  • the propellant gases which can be used to produce the inhalation aerosols according to the invention are known from the prior art.
  • Suitable propellants are selected from the group consisting of hydrocarbons such as n-propane, n-butane or isobutane and halogenated hydrocarbons such as chlorinated and / or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the above-mentioned propellant gases can be used alone or in mixtures thereof.
  • Particularly preferred propellant gases are halogenated alkane derivatives selected from the group consisting of TG11, TG 12, TG 134a and TG227.
  • TG 134a (1,1, 1, 2-tetrafluoroethane) and the TG227 (1, 1, 1, 2,3,3,3-heptafluoropropane) and mixtures thereof are preferred according to the invention.
  • the inhalation aerosols containing propellant gas according to the invention can furthermore contain further constituents such as cosolvents, stabilizers, surfactants, antioxidants, lubricants and agents for adjusting the pH. All of these components are known in the art.
  • the inhalation aerosols containing propellant gas according to the invention can contain up to 5% by weight of active ingredient 1 and / or 2. Aerosols according to the invention contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1 % By weight of active ingredient 1 and / or 2. If the active ingredients 1 and / or 2 are in dispersed form, the active ingredient particles preferably have an average particle size of up to 10 ⁇ m, preferably from 0.1 to 5 ⁇ m, particularly preferably from 1 to 5 ⁇ m.
  • the present invention further relates to inhalers, characterized in that they contain propellant-containing aerosols according to the invention described above.
  • the present invention further relates to cartridges which can be used with a suitable valve in a suitable inhaler and which contain one of the above-mentioned inhalation aerosols containing propellant gas according to the invention. Suitable cartridges and methods for filling these cartridges with the inhalation aerosols containing propellant gas according to the invention are known from the prior art.
  • the active compound combination according to the invention is particularly preferably applied in the form of propellant-free inhalation solutions and inhalation suspensions.
  • Suitable solvents for this purpose are aqueous or alcoholic, preferably ethanolic, solutions.
  • the solvent can only be water or it is a mixture of water and ethanol.
  • the relative proportion of ethanol to water is not limited, but the maximum limit is preferably up to 70 percent by volume, in particular up to 60 percent by volume and particularly preferably up to 30 percent by volume.
  • the remaining volume percentages are filled up with water.
  • the solutions and suspensions containing 1 and 2, separately or together, are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. Acids selected from inorganic or organic acids can be used to adjust this pH.
  • Examples of particularly suitable inorganic acids are hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and / or phosphoric acid.
  • Examples of particularly suitable organic acids are: ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and / or Propionic acid and others.
  • Preferred inorganic acids are hydrochloric acid, sulfuric acid. It is also possible to use the acids which already form an acid addition salt with one of the active ingredients. Ascorbic acid, fumaric acid and citric acid are preferred among the organic acids.
  • mixtures of the acids mentioned can also be used, in particular in cases of acids which, in addition to their acidifying properties, also have other properties, for example as flavorings, antioxidants or complexing agents, such as, for example, citric acid or ascorbic acid.
  • hydrochloric acid is particularly preferably used to adjust the pH.
  • the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as a stabilizer or complexing agent can be dispensed with in the present formulation.
  • Other embodiments include this connection (s).
  • the content based on sodium edetate is less than 100 mg / 100 ml, preferably less than 50 mg / 100 ml, particularly preferably less than 20 mg / 100 ml.
  • Co-solvents and / or further auxiliaries can be added to the propellant-free inhalation solutions according to the invention.
  • Preferred co-solvents are those which contain hydroxyl groups or other polar groups, for example alcohols - in particular isopropyl alcohol, glycols
  • auxiliary substances and additives are understood to mean any pharmacologically acceptable substance which is not an active substance, but together with the active substance (s) in the pharmacologically suitable one
  • auxiliaries and additives include e.g. surfactants such as Soy lecithin, oleic acid, sorbitan esters, such as
  • Antioxidants and / or preservatives that ensure or extend the useful life of the finished pharmaceutical formulation, flavors.
  • To The additives also include pharmacologically acceptable salts such as sodium chloride as isotonic agents.
  • the preferred auxiliary substances include antioxidants, such as, for example, ascorbic acid, unless already used for adjusting the pH, vitamin A, vitamin E, tocopherols and similar vitamins or provitamins occurring in the human organism.
  • Preservatives can be used to protect the formulation from contamination with germs. Suitable preservatives are those known from the prior art, in particular cetylpyridinium chloride,
  • Benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art.
  • the preservatives mentioned above are preferably present in concentrations of up to 50 mg / 100 ml, particularly preferably between 5 and 20 mg / 100 ml.
  • preferred formulations only contain benzalkonium chloride and sodium edetate. In another preferred embodiment, sodium edetate is dispensed with.
  • those inhalers which can nebulize a small amount of a liquid formulation in the therapeutically necessary dosage within a few seconds into an aerosol suitable for therapeutic inhalation.
  • those nebulizers are preferred in which an amount of less than 100 ⁇ L, preferably less than 50 ⁇ L, particularly preferably between 20 and 30 ⁇ L of active ingredient solution, preferably with a stroke to an aerosol with an average particle size of less than 20 ⁇ m, preferably less than 10 ⁇ m, can be atomized in such a way that the inhalable portion of the aerosol already corresponds to the therapeutically effective amount.
  • Such a device for propellant-free administration of a metered amount of a liquid medicinal product for inhalation use is described in detail, for example, in international patent application WO 91/14468 and also in WO 97/12687 (there in particular FIGS. 6a and 6b).
  • the nebulizers described there are also known under the name Respimat ® .
  • This nebuliser may be advantageous to produce the inhalable aerosols according to the invention containing the combination of active substances and are used. 2 Because of its cylinder-like shape and a Handy size of less than 9 to 15 cm in length and 2 to 4 cm in width, this device can be carried by the patient at any time.
  • the nebulizer sprays a defined volume of the drug formulation using high pressures through small nozzles, so that inhalable aerosols are formed.
  • the preferred atomizer consists of an upper housing part, a pump housing, a nozzle, a locking mechanism, a spring housing, a spring and a storage container, characterized by a pump housing which is fastened in the upper housing part and which has a nozzle body with the nozzle at one end or nozzle arrangement carries, a hollow piston with valve body, an output flange in which the hollow piston is fastened, and which is in the
  • Upper housing part is - a locking mechanism, which is located in the upper housing part, a spring housing with the spring therein, which is rotatably mounted on the upper housing part by means of a rotary bearing, a lower housing part which is attached to the spring housing in the axial direction.
  • the hollow piston with valve body corresponds to a device disclosed in WO 97/12687. It projects partially into the cylinder of the pump housing and is arranged axially displaceably in the cylinder. In particular, reference is made to FIGS. 1-4 - in particular FIG. 3 - and the associated parts of the description.
  • the hollow piston with valve body exerts a pressure of 5 to 60 Mpa (about 50 to 600 bar), preferably 10 to 60 Mpa (about 100 to 600 bar) on the fluid, the measured active ingredient solution on its high pressure side at the time the spring is triggered. Volumes of 10 to 50 microliters are preferred, volumes of 10 to 20 microliters are particularly preferred, and a volume of 15 microliters per stroke is very particularly preferred.
  • the valve body is preferably attached to the end of the hollow piston which faces the nozzle body.
  • the nozzle in the nozzle body is preferably microstructured, that is to say manufactured by micro technology.
  • Microstructured nozzle bodies are disclosed, for example, in WO-94/07607; reference is hereby made to this document, in particular to FIG. 1 disclosed there and its description.
  • the nozzle body consists, for example, of two firmly connected plates made of glass and / or silicon, of which at least one plate has one or more microstructured channels which connect the nozzle inlet side to the nozzle outlet side.
  • On the nozzle outlet side there is at least one round or non-round opening of 2 to 10 micrometers deep and 5 to 15 micrometers wide, the depth preferably being 4.5 to 6.5 micrometers and the length being 7 to 9 micrometers.
  • the jet directions of the nozzles in the nozzle body can run parallel to one another or they are inclined towards one another in the direction of the nozzle opening.
  • the jet directions can be inclined at an angle of 20 degrees to 160 degrees, an angle of 60 to 150 degrees is preferred, particularly preferably 80 to 100 °.
  • the nozzle openings are preferably arranged at a distance of 10 to 200 micrometers, more preferably at a distance of 10 to 100 micrometers, particularly preferably 30 to 70 micrometers. Most preferred are 50 microns.
  • the jet directions meet in the vicinity of the nozzle openings.
  • the liquid pharmaceutical preparation hits the nozzle body at an inlet pressure of up to 600 bar, preferably 200 to 300 bar, and is atomized into an inhalable aerosol via the nozzle openings.
  • the preferred particles Droplet sizes of the aerosol are up to 20 micrometers, preferably 3 to 10 micrometers.
  • the locking mechanism contains a spring, preferably a cylindrical helical compression spring, as a store for the mechanical energy.
  • the spring acts on the output flange as a jumping piece, the movement of which is determined by the position of a locking element.
  • the path of the output flange is precisely limited by an upper and a lower stop.
  • the spring is preferably via a force-transmitting gear, e.g. a screw-type thrust gear, tensioned by an external torque generated when the upper housing part is turned against the spring housing in the lower housing part.
  • the upper part of the housing and the output flange contain a single or multi-speed wedge gear.
  • the locking member with engaging locking surfaces is arranged in a ring around the output flange. It consists, for example, of a radially elastically deformable ring made of plastic or metal. The ring is perpendicular to the plane Atomizer axis arranged. After tensioning the spring, the locking surfaces of the locking member slide into the path of the output flange and prevent the spring from relaxing.
  • the locking element is triggered by a button.
  • the trigger button is connected or coupled to the locking member. To release the locking mechanism, the release button is moved parallel to the ring plane, and preferably into the atomizer; the deformable ring is deformed in the plane of the ring. Structural details of the locking mechanism are described in WO 97/20590.
  • the lower part of the housing is pushed in the axial direction over the spring housing and covers the bearing, the drive of the spindle and the reservoir for the fluid.
  • the upper housing part When the atomizer is actuated, the upper housing part is rotated against the lower housing part, the lower housing part taking the spring housing with it.
  • the spring is compressed and tensioned via the screw-type thrust gear, and the locking mechanism engages automatically.
  • the angle of rotation is preferably an integer fraction of 360 degrees, e.g. 180 degrees.
  • the driven part in the upper part of the housing is shifted by a predetermined distance, the hollow piston is withdrawn inside the cylinder in the pump housing, whereby a part of the fluid is sucked out of the reservoir into the high-pressure space in front of the nozzle.
  • the storage container contains the aqueous aerosol preparation according to the invention.
  • the atomization process is initiated by gently pressing the trigger button.
  • the barrage clears the way for the stripping section.
  • the tensioned spring pushes the piston into the cylinder of the pump housing.
  • the components of the atomizer are made of a material that is suitable for their function.
  • the housing of the atomizer and - as far as the function allows - other parts are preferably made of plastic, for example in the Injection molding process. Physiologically harmless materials are used for medical purposes.
  • FIGS. 6 a / b of WO 97/12687 describe the nebulizer (Respimat ⁇ ) with which the aqueous aerosol preparations according to the invention can advantageously be inhaled.
  • Figure 6a of WO 97/12687 shows a longitudinal section through the atomizer with the spring under tension.
  • Figure 6b of WO 97/12687 shows a longitudinal section through the atomizer with the spring relaxed.
  • the upper housing part (51) contains the pump housing (52), at the end of which the holder (53) for the atomizer nozzle is attached.
  • the nozzle body (54) and a filter (55) are located in the holder.
  • the hollow piston (57) fastened in the output flange (56) of the locking tension mechanism partially projects into the cylinder of the pump housing.
  • the hollow piston carries the valve body (58) at its end.
  • the hollow piston is sealed by means of the seal (59).
  • Inside the upper part of the housing is the stop (60), against which the output flange rests when the spring is relaxed.
  • the stop (61) is located on the output flange, against which the output flange rests when the spring is tensioned.
  • the locking member (62) slides between the stop (61) and a support (63) in the upper part of the housing.
  • the release button (64) is connected to the locking member.
  • the upper housing part ends in the mouthpiece (65) and is closed with the clip-on protective cap (66).
  • the spring housing (67) with compression spring (68) is rotatably mounted on the upper part of the housing by means of the snap lugs (69) and rotary bearings.
  • the lower housing part (70) is pushed over the spring housing.
  • the exchangeable storage container (71) for the fluid (72) to be atomized is located within the spring housing.
  • the storage container is closed with the stopper (73) through which the hollow piston protrudes into the storage container and with its end is immersed in the fluid (supply of active substance solution).
  • the spindle (74) for the mechanical counter is mounted in the outer surface of the spring housing.
  • the drive pinion (75) is located at the end of the spindle which faces the upper housing part.
  • the rider (76) sits on the spindle.
  • the mass expelled, in at least 97%, preferably at least 98% of all actuations of the inhaler (hub) correspond to a defined amount with a tolerance range of at most 25%, preferably 20% of this amount.
  • Between 5 and 30 mg of formulation are preferably applied as a defined mass per stroke, particularly preferably between 5 and 20 mg.
  • formulation according to the invention can also be nebulized using inhalers other than those described above, for example jet stream inhalers.
  • a further aspect of the present invention relates to medicaments in the form of above-described propellant-free inhalable solutions or suspensions in combination with a suitable device for administering these formulations, preferably in conjunction with the Respimat ®.
  • the present invention to propellant-free inhalable solutions or suspensions characterized by the aims of the invention combination of active substances 1 and 2 in connection with the known under the name Respimat ® device.
  • the present invention relates to the abovementioned devices for inhalation preferred Respimat ®, in the fact that they contain according to the invention the propellant-free inhalable solutions or suspensions as described above.
  • the propellant-free inhalation solutions or suspensions according to the invention can, in addition to the solutions and suspensions intended for application in the Respimat, also be present as concentrates or sterile, ready-to-use inhalation solutions or suspensions.
  • Ready-to-use formulations can be generated from the concentrates, for example, by adding isotonic saline solutions.
  • Sterile, ready-to-use formulations can be applied using energy-operated stand-up or portable nebulisers that generate inhalable aerosols using ultrasound or compressed air according to the Venturi principle or other principles.
  • a further aspect of the present invention relates to medicaments in the form of propellant-free inhalable solutions or suspensions as described above, which are present as concentrates or sterile, ready-to-use formulations, in conjunction with a

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouvelles compositions médicamenteuses à base de nouveaux anticholinergiques et antagonistes du récepteur NK1, des procédés permettant de les produire, ainsi que leur utilisation dans le traitement de maladies des voies respiratoires.
EP03762508A 2002-07-09 2003-06-25 Nouvelles compositions medicamenteuses a base de nouveaux anticholinergiques et antagonistes du recepteur nk1 Ceased EP1521580A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10230750A DE10230750A1 (de) 2002-07-09 2002-07-09 Neue Arzneimittelkompositionen auf der Basis neuer Anticholonergika und NK1-Rezeptor-Antagonisten
DE10230750 2002-07-09
PCT/EP2003/006667 WO2004004724A1 (fr) 2002-07-09 2003-06-25 Nouvelles compositions medicamenteuses a base de nouveaux anticholinergiques et antagonistes du recepteur nk1

Publications (1)

Publication Number Publication Date
EP1521580A1 true EP1521580A1 (fr) 2005-04-13

Family

ID=29761745

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762508A Ceased EP1521580A1 (fr) 2002-07-09 2003-06-25 Nouvelles compositions medicamenteuses a base de nouveaux anticholinergiques et antagonistes du recepteur nk1

Country Status (6)

Country Link
EP (1) EP1521580A1 (fr)
JP (1) JP2005532378A (fr)
AU (1) AU2003242754A1 (fr)
CA (1) CA2491451A1 (fr)
DE (1) DE10230750A1 (fr)
WO (1) WO2004004724A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203139A1 (en) * 2004-04-14 2007-08-30 Astrazeneca Ab Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW449590B (en) * 1995-04-14 2001-08-11 Boehringer Ingelheim Kg New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
DE19608665A1 (de) * 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
DE10051320A1 (de) * 2000-10-17 2002-04-25 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten
CA2432543A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicaments de combinaison

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004004724A1 *

Also Published As

Publication number Publication date
WO2004004724A1 (fr) 2004-01-15
CA2491451A1 (fr) 2004-01-15
JP2005532378A (ja) 2005-10-27
DE10230750A1 (de) 2004-01-22
AU2003242754A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
EP2105143B1 (fr) Compositions pharmaceutiques basées sur des séls de tiotropium et ceclesonide
EP1530471B1 (fr) Medicament a inhaler contenant un nouvel anticholinergique en combinaison avec des corticosteroides et de betamimetiques
EP1335728A1 (fr) Nouvelles compositions de medicaments a base de sels de tiotropium et de sels de salmeterol
EP1357975A1 (fr) Compositions medicamenteuses contenant des betamimetiques et ayant des effets secondaires limites
EP1732553A1 (fr) Composes pour traiter des processus de proliferation
WO2002036106A2 (fr) Nouvelle composition medicamenteuse a base d'anticholinergiques et de corticosteroides
WO2003087049A2 (fr) Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
WO2006056527A1 (fr) Medicaments administres par inhalation contenant un anticholinergique, du salmeterol et un steroide du groupe ciclesonide ou mometasone furoate
WO2003066044A1 (fr) Nouvelles compositions de medicaments contenant, outre des anticholinergiques, des composes heterocycliques
WO2003086399A1 (fr) Medicament contenant des steroides et un nouvel anticholinergique
WO2002060533A2 (fr) Compositions medicamenteuses a faibles effets secondaires
EP1521576A1 (fr) Nouvelles compositions pharmaceutiques comprenant de nouveaux agents anticholinergiques et des inhibiteurs de la pde-iv
DE10111058A1 (de) Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten
EP1827432A1 (fr) Medicaments administres par inhalation contenant un nouvel anticholinergique, du formoterol et un steroide
EP1379225A2 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de l'endotheline
EP1341538A2 (fr) Nouvelles compositions de medicaments
WO2004004724A1 (fr) Nouvelles compositions medicamenteuses a base de nouveaux anticholinergiques et antagonistes du recepteur nk1
EP1581224B1 (fr) Preparation medicamenteuse a inhaler contenant du tiotropium
WO2002049624A2 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'agonistes de la dopamine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20070413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100726